Stimulating β-Cell Regeneration by Combining a GPR119 Agonist with a DPP-IV Inhibitor
Figure 3
(A) OGTT in non-diabetic control mice and diabetic mice treated with vehicle, and those that achieved normoglycemia after 7 weeks treatment with PSN632408, sitagliptin, or PSN632408 and sitagliptin combination (n = 5 mice per group).
Blood glucose levels in mice treated with PSN632408 and sitagliptin combination were significantly lower than in mice treated with PSN632408 alone at 45 minutes and at 90 minutes (p<0.01) and in mice treated with sitagliptin alone at 90 minutes (p<0.01). (B) Blood glucose AUC0–120 in mice treated with PSN632408, sitagliptin, or PSN632408 and sitagliptin combination was significantly lower than in mice treated with vehicle (P<0.01).